Nootropics are a broad class of medications encompassing many different mechanisms of action that are marketed as cognitive enhancers. Not only do most nootropics lack evidence of efficacy, but some can have dangerous side effects and addictive potential. Here, we discuss some of the most concerning nootropics being widely used today.

Incarcerated individuals with opioid use disorder are at an especially heightened risk of adverse outcomes.  The period immediately following release is a particularly vulnerable time, with a much elevated risk of fatal overdose. In this study, investigators report on the use of extended-release injectable buprenorphine in a correctional setting.

Despite its high prevalence, morbidity, and mortality, our treatment options for alcohol use disorder are limited. Severe alcohol use disorder can be especially challenging to treat. Here, researchers demonstrate the efficacy and feasibility of a novel treatment option: deep brain stimulation.

Sexual addictions are rarely discussed with patients, even among addiction specialists. Societal taboos, social norms, and stigma can make it difficult for patients to discuss sexual issues with their providers. In this interview, Dr. Turner gives us tips in history gathering and covers what you need to know about diagnosis and treatment.

Gambling disorder is much more prevalent than many providers realize, and it is a condition that is rarely screened for, let alone treated, by mental health professionals. Here, Dr. Fong reviews the topic, walks us through how to take a good gambling history, make a diagnosis, and how to provide the best treatment.

By successfully completing the test you will be awarded a certificate for 2 CME credit.

Pregnant patients with OUD may be reluctant to reveal their substance use for fear of losing their baby if reported to Child Protective Services. But this recent study shows that pregnant patients receiving medication treatment for OUD were more likely to leave the hospital with their baby than patients not receiving treatment.

Recent preliminary research reveals that psilocybin helped participants with alcohol use disorder cut back on drinking. Dive in to discover how this psychedelic compound might offer hope for patients who have found other current treatments ineffective.

Xylazine is the latest contaminant being found in the American illicit drug supply. A non-opioid itself, xylazine is usually combined with fentanyl, with which it has synergistic sedative effects. Patients using xylazine can have profound levels of sedation and develop severe peripheral wounds. In this article, we discuss xylazine essentials and cover harm reduction strategies to help keep your patients safe.